Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer
Background: Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype of breast cancer with poor survival. Currently, the literature lacks comprehensive real-world evidence on locally recurrent and mTNBC patients. To validate the optimal treatment for patients with mTNBC, real-world...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-10-01
|
| Series: | Breast Cancer: Basic and Clinical Research |
| Online Access: | https://doi.org/10.1177/11782234231203292 |
| _version_ | 1797666302694785024 |
|---|---|
| author | Alan Celik Tobias Berg Maj-Britt Jensen Erik Jakobsen Hanne Melgaard Nielsen Iben Kümler Vesna Glavicic Jeanette Dupont Jensen Ann Knoop |
| author_facet | Alan Celik Tobias Berg Maj-Britt Jensen Erik Jakobsen Hanne Melgaard Nielsen Iben Kümler Vesna Glavicic Jeanette Dupont Jensen Ann Knoop |
| author_sort | Alan Celik |
| collection | DOAJ |
| description | Background: Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype of breast cancer with poor survival. Currently, the literature lacks comprehensive real-world evidence on locally recurrent and mTNBC patients. To validate the optimal treatment for patients with mTNBC, real-world evidence in combination with data from clinical trials must be evaluated as complementary. Objectives: The objective of the study is to examine outcomes and treatment patterns of patients with advanced triple-negative breast cancer (TNBC) utilizing real-world data of patients from all oncology sites across Denmark. Design: This is a retrospective, non-interventional, multi-site, population-based observational study conducted across all oncology departments in Denmark. Methods: We included all women diagnosed with metastatic or locally recurrent TNBC from January 1, 2017, to December 31, 2019, using the national Danish Breast Cancer Group database. The primary endpoints were overall survival (OS) and progression-free survival (PFS) in the first to third treatment line. Results: The study included 243 women diagnosed with metastatic or recurrent TNBC. The median OS (mOS) was 11.6 months after the first line of treatment, 6.5 months after the second line, and 6.5 months after the third line. De novo mTNBC was associated with shorter OS (mOS: 8.3 vs 14.2 months), and those with a relapse within 18 months of primary diagnosis had shorter OS than those with a relapse after 18 months (mOS: 10.0 vs 18.2). In the first line, taxane was the preferred choice of treatment for patients with de novo mTNBC, whereas capecitabine was preferred for patients with recurrent TNBC. Conclusions: This real-world, nationwide study demonstrated poor OS among patients with metastatic or recurrent TNBC, with a mOS of 11.6 months (95% CI, 9.9-17.3). Patients who presented with de novo mTNBC or who had a relapse of their breast cancer within 18 months of primary diagnosis had shorter OS. Registration The study was registered and approved by the Danish Capital Regions research overview (P-2021-605). |
| first_indexed | 2024-03-11T19:57:38Z |
| format | Article |
| id | doaj.art-8667cce3158e4750a5ea7c2781852e06 |
| institution | Directory Open Access Journal |
| issn | 1178-2234 |
| language | English |
| last_indexed | 2024-03-11T19:57:38Z |
| publishDate | 2023-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Breast Cancer: Basic and Clinical Research |
| spelling | doaj.art-8667cce3158e4750a5ea7c2781852e062023-10-04T17:03:20ZengSAGE PublishingBreast Cancer: Basic and Clinical Research1178-22342023-10-011710.1177/11782234231203292Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast CancerAlan Celik0Tobias Berg1Maj-Britt Jensen2Erik Jakobsen3Hanne Melgaard Nielsen4Iben Kümler5Vesna Glavicic6Jeanette Dupont Jensen7Ann Knoop8Danish Breast Cancer Group (DBCG), Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkDepartment of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkDanish Breast Cancer Group (DBCG), Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkDepartment of Oncology, Hospital of Southern Jutland Sonderborg Branch, Sonderborg, DenmarkDepartment of Oncology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Oncology, Herlev Hospital, Herlev, DenmarkDepartment of Oncology, Zealand University Hospital, Naestved, DenmarkDepartment of Oncology, Odense University Hospital, Odense, DenmarkDepartment of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkBackground: Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype of breast cancer with poor survival. Currently, the literature lacks comprehensive real-world evidence on locally recurrent and mTNBC patients. To validate the optimal treatment for patients with mTNBC, real-world evidence in combination with data from clinical trials must be evaluated as complementary. Objectives: The objective of the study is to examine outcomes and treatment patterns of patients with advanced triple-negative breast cancer (TNBC) utilizing real-world data of patients from all oncology sites across Denmark. Design: This is a retrospective, non-interventional, multi-site, population-based observational study conducted across all oncology departments in Denmark. Methods: We included all women diagnosed with metastatic or locally recurrent TNBC from January 1, 2017, to December 31, 2019, using the national Danish Breast Cancer Group database. The primary endpoints were overall survival (OS) and progression-free survival (PFS) in the first to third treatment line. Results: The study included 243 women diagnosed with metastatic or recurrent TNBC. The median OS (mOS) was 11.6 months after the first line of treatment, 6.5 months after the second line, and 6.5 months after the third line. De novo mTNBC was associated with shorter OS (mOS: 8.3 vs 14.2 months), and those with a relapse within 18 months of primary diagnosis had shorter OS than those with a relapse after 18 months (mOS: 10.0 vs 18.2). In the first line, taxane was the preferred choice of treatment for patients with de novo mTNBC, whereas capecitabine was preferred for patients with recurrent TNBC. Conclusions: This real-world, nationwide study demonstrated poor OS among patients with metastatic or recurrent TNBC, with a mOS of 11.6 months (95% CI, 9.9-17.3). Patients who presented with de novo mTNBC or who had a relapse of their breast cancer within 18 months of primary diagnosis had shorter OS. Registration The study was registered and approved by the Danish Capital Regions research overview (P-2021-605).https://doi.org/10.1177/11782234231203292 |
| spellingShingle | Alan Celik Tobias Berg Maj-Britt Jensen Erik Jakobsen Hanne Melgaard Nielsen Iben Kümler Vesna Glavicic Jeanette Dupont Jensen Ann Knoop Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer Breast Cancer: Basic and Clinical Research |
| title | Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer |
| title_full | Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer |
| title_fullStr | Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer |
| title_full_unstemmed | Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer |
| title_short | Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer |
| title_sort | real world survival and treatment regimens across first to third line treatment for advanced triple negative breast cancer |
| url | https://doi.org/10.1177/11782234231203292 |
| work_keys_str_mv | AT alancelik realworldsurvivalandtreatmentregimensacrossfirsttothirdlinetreatmentforadvancedtriplenegativebreastcancer AT tobiasberg realworldsurvivalandtreatmentregimensacrossfirsttothirdlinetreatmentforadvancedtriplenegativebreastcancer AT majbrittjensen realworldsurvivalandtreatmentregimensacrossfirsttothirdlinetreatmentforadvancedtriplenegativebreastcancer AT erikjakobsen realworldsurvivalandtreatmentregimensacrossfirsttothirdlinetreatmentforadvancedtriplenegativebreastcancer AT hannemelgaardnielsen realworldsurvivalandtreatmentregimensacrossfirsttothirdlinetreatmentforadvancedtriplenegativebreastcancer AT ibenkumler realworldsurvivalandtreatmentregimensacrossfirsttothirdlinetreatmentforadvancedtriplenegativebreastcancer AT vesnaglavicic realworldsurvivalandtreatmentregimensacrossfirsttothirdlinetreatmentforadvancedtriplenegativebreastcancer AT jeanettedupontjensen realworldsurvivalandtreatmentregimensacrossfirsttothirdlinetreatmentforadvancedtriplenegativebreastcancer AT annknoop realworldsurvivalandtreatmentregimensacrossfirsttothirdlinetreatmentforadvancedtriplenegativebreastcancer |